Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition

Initial Phase 2b data for sutacimig in Factor VII deficiency showed multi-fold accumulation of endogenous FVII(a) and shortened prothrombin time after a single subcutaneous dose. The early findings are positive pharmacodynamic signals; the report provides no participant count or numerical effect sizes.